GNAS
GNAS (Neuroendocrine secretory protein 55) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Pancreatic ductal adenocarcinoma, Breast cancer and 5 more.
Overview
UniProt has no function text for O95467; HGNC names it "GNAS complex locus".
CIViC holds 17 clinical evidence items and 0 assertions across 5 variants, naming Trametinib, Palbociclib, Vemurafenib and Gefitinib and others. Open Targets scores its association with cancer at 0.77 (direct and indirect evidence; datatypes genetic literature 0.30, affected pathway 0.61, literature 0.98, genetic association 0.03, somatic mutation 0.97, animal model 0.25). IntOGen calls it a driver in 12 cohorts (11 activating, 1 loss-of-function), covering Invasive Breast Carcinoma, Colorectal Adenocarcinoma, Oesophageal Adenocarcinoma, Hepatocellular Carcinoma, Lung Adenocarcinoma, Medulloblastoma and others.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · GNAS (Neuroendocrine secretory protein 55) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Pancreatic ductal adenocarcinoma, Breast cancer and 5 more.
- 1 · What it is
GNAS (Neuroendocrine secretory protein 55) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Pancreatic ductal adenocarcinoma, Breast cancer and 5 more.
- 2 · What goes wrong in cancer
UniProt has no function text for O95467; HGNC names it "GNAS complex locus". Location: Cytoplasmic vesicle, secretory vesicle; Secreted (UniProt).
- 3 · How drugs use it
No product in this corpus aims at GNAS yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
External identifiers
Sources: HGNC HGNC:4392 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O95467 (protein name, function text, keywords and locations (REST API)); CIViC gene GNAS (17 evidence items, 0 assertions, 5 variants; diseases: Colorectal Cancer, Pseudomyxoma Peritonei, Appendix Cancer, Melanoma, Lung Non-small Cell Carcinoma and 9 more (GraphQL API, CC0)); Open Targets ENSG00000087460 (association with cancer (MONDO_0004992) 0.77; per-cancer scores at or above 0.5: colorectal cancer 0.67, gastric cancer 0.51, ovarian cancer 0.51, melanoma 0.57, skin cancer 0.57 (GraphQL API, CC0)); IntOGen GNAS (driver in 12 cohorts (Act 11, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
UniProt has no function text for O95467; HGNC names it "GNAS complex locus". Location: Cytoplasmic vesicle, secretory vesicle; Secreted (UniProt). Locus 20q13.32 (HGNC).
- Colorectal cancer: Open Targets association 0.67 with colorectal cancer (MONDO_0005575); CIViC evidence names this disease
- Pancreatic ductal adenocarcinoma: CIViC evidence names this disease; IntOGen driver in 5 cohorts (PAAD, PANCREAS)
- Breast cancer: CIViC evidence names this disease; IntOGen driver in 2 cohorts (BRCA)
- Bladder & urothelial cancer: CIViC evidence names this disease
- Oesophageal cancer: CIViC evidence names this disease; IntOGen driver in 1 cohort (ESCA)
- Skin cancer: Open Targets association 0.57 with skin cancer (MONDO_0002898)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 11 therapies; IntOGen calls it an activating (Act) driver in 11 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; CIViC holds 17 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Pseudomyxoma Peritonei; Appendix Cancer; Follicular Thyroid Carcinoma; Histiocytosis-Lymphadenopathy Plus Syndrome.
Latest papers
topQuery for this target: (TITLE:"GNAS" OR ABSTRACT:"GNAS" OR TITLE:"GNAS complex locus" OR ABSTRACT:"GNAS complex locus" OR TITLE:"Neuroendocrine secretory protein 55" OR ABSTRACT:"Neuroendocrine secretory protein 55" OR TITLE:"NESP55" OR ABSTRACT:"NESP55" OR TITLE:"GNASXL" OR ABSTRACT:"GNASXL" OR TITLE:"SCG6" OR ABSTRACT:"SCG6") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about GNAS, not a curated reading list.